Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Wellness Institute Earthmends Line Targets Cancer Patients

This article was originally published in The Tan Sheet

Executive Summary

Earthmends, a new line of dietary supplements marketed by the Cancer Wellness Institute, is claimed to "nutritionally aid people in cancer prevention and treatment support."

You may also be interested in...



Earthmends Breast, Prostate Health Formula Claims Under FDA Review

The Cancer Wellness Institute's line of Earthmends Breast Health and Prostate Health dietary supplements will continue to carry claims they provide nutritional support for individuals undergoing cancer treatment or trying to prevent cancer, the Palm Harbor, Fla.-based company said.

Earthmends Breast, Prostate Health Formula Claims Under FDA Review

The Cancer Wellness Institute's line of Earthmends Breast Health and Prostate Health dietary supplements will continue to carry claims they provide nutritional support for individuals undergoing cancer treatment or trying to prevent cancer, the Palm Harbor, Fla.-based company said.

Earthmends Breast, Prostate Health Formula Claims Under FDA Review

The Cancer Wellness Institute's line of Earthmends Breast Health and Prostate Health dietary supplements will continue to carry claims they provide nutritional support for individuals undergoing cancer treatment or trying to prevent cancer, the Palm Harbor, Fla.-based company said.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel